Table of Contents  

Cell therapy for cancer – our synthetic future

Carl H June
Published in : HAMDAN MEDICAL JOURNAL ; Vol 7, No 4 (2014): Volume 7 Supplement 1
DOI : 10.7707/hmj.392

Abstract


It is now well established that the immune system can control and eliminate cancer cells. Adoptive T-cell transfer has the potential to overcome the significant limitations associated with vaccine-based strategies in patients who are often immunocompromised. Application of the emerging discipline of synthetic biology to cancer, which combines elements of genetic engineering and molecular biology to create new biological structures with enhanced functionalities, is the subject of this lecture. Various chimeric antigen receptor designs, manufacturing processes and study populations, among other variables, have been tested and reported in recent clinical trials. Our most recent results from studies in acute and chronic leukaemia indicate potent and durable responses in adults and children with advanced leukaemia. Many questions remain in the field of engineered T cells, but the encouraging response rates pave a wide road for future investigation.

 


View article in  :   PDF     HTML    



Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA